12/30
03:33 pm
cybn
Cybin Initiates At-The-Market Equity Program of up to US$100 Million
Medium
Report
Cybin Initiates At-The-Market Equity Program of up to US$100 Million
12/18
12:29 pm
cybn
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
Low
Report
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
12/18
11:53 am
cybn
KILL Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq [Yahoo! Finance]
Low
Report
KILL Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq [Yahoo! Finance]
12/18
08:13 am
cybn
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq [Yahoo! Finance]
Low
Report
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq [Yahoo! Finance]
12/18
07:30 am
cybn
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
Low
Report
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
12/3
08:44 am
cybn
Cybin (OTCMKTS:CYBN) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Cybin (OTCMKTS:CYBN) had its "buy" rating reaffirmed by analysts at Guggenheim.
11/20
08:10 pm
cybn
Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges [Yahoo! Finance]
Medium
Report
Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges [Yahoo! Finance]
11/20
11:04 am
cybn
Cybin (OTCMKTS:CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $70.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Cybin (OTCMKTS:CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $70.00 to $45.00. They now have a "buy" rating on the stock.
11/14
01:59 pm
cybn
Cybin (OTCMKTS:CYBN) had its price target lowered by analysts at HC Wainwright from $150.00 to $55.00. They now have a "buy" rating on the stock.
Low
Report
Cybin (OTCMKTS:CYBN) had its price target lowered by analysts at HC Wainwright from $150.00 to $55.00. They now have a "buy" rating on the stock.
11/14
05:31 am
cybn
Fibroblast Growth Factors Market Global Forecast Report 2025-2030: Opportunities in Regenerative Medicine, Oncology, and Metabolic Disorders Due to Advances in Molecular Biology, Delivery Technologies [Yahoo! Finance]
Low
Report
Fibroblast Growth Factors Market Global Forecast Report 2025-2030: Opportunities in Regenerative Medicine, Oncology, and Metabolic Disorders Due to Advances in Molecular Biology, Delivery Technologies [Yahoo! Finance]